KEYTRUDA® (pembrolizumab) of Merck Receives Positive CHMP Opinion for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

Merck Igea Luca Dezzani

merck

June 27, 2016

Merck, known as MSD outside the United States and Canada, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for treating locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults who have received at least one prior chemotherapy regimen and whose tumors express PD-L1. This CHMP positive opinion for KEYTRUDA will now be reviewed by the European Commission for marketing authorization in the European Union (EU).

“This news marks an important step in making KEYTRUDA available for appropriate patients suffering from locally advanced or metastatic non-small cell lung cancer. We are grateful to patients and investigators around the world who participated in these studies and who are helping to advance this important new treatment,” said Dr. Roger Dansey, senior vice president and therapeutic area head, oncology late-stage development, Merck Research Laboratories.

Data supporting the CHMP positive opinion were based on findings from two studies, KEYNOTE-001, which assessed overall response rates (ORR), and KEYNOTE-010, a pivotal study assessing overall survival (OS).

Advertisements

Novartis announces long-term safety data of Revolade® in adults with chronic immune thrombocytopenia

novartis

June 10, 2016

Novartis has announced data from the largest study of its kind confirming the long-term safety profile of Revolade (eltrombopag) in adults suffering from chronic immune (idiopathic) thrombocytopenia (ITP), with data for up to 6 years in some patients (median exposure was 2.4 years). More data from the study would also show that long-term oral administration of Revolade was effective in increasing and maintaining platelet counts in adult patients who had their spleens removed (splenectomized) as well as those who did not (non-splenectomized). Final results of the study and sub-analysis will be presented at the 21st Congress of the European Hematology Association (EHA) in Copenhagen, Denmark.

ITP is a potentially serious and rare type of blood disorder where the blood doesn’t clot as it should because of a low number of platelets. Consequently, patients experience bleeding, bruising, and in some cases, serious hemorrhage that can be deadly. ITP may also affect the quality of life of the patients, as it is often associated with depression and fatigue, as well as a fear of bleeding that may limit everyday activities.

“Patients living with chronic diseases will likely remain on therapy for many years, so data about the long-term use of treatments, particularly around safety, are critical. EXTEND is the largest study of its kind and reinforces Revolade as a trusted option that adults with chronic ITP can use for the long-term,” said Alessandro Riva, MD, Global Head, Novartis Oncology Development and Medical Affairs.

Data presented by Novartis showing Jakavi® is superior to best available therapy in patients with less advanced polycythemia vera (PV)

novartis

June 10, 2016

Novartis has announced Phase III data from RESPONSE-2 revealing that Jakavi®(ruxolitinib) assisted patients with polycythemia vera (PV), who were resistant to or intolerant of hydroxyurea and did not have an enlarged spleen, achieve superior hematocrit control compared to best available therapy (BAT) at 28 weeks (62.2% vs 18.7%, respectively; p<0.0001). These findings were presented at the 21st Congress of the European Hematology Association (EHA) in Copenhagen, Denmark for the first time.

Polycythemia vera is an incurable and rare blood cancer associated with an overproduction of blood cells causing serious cardiovascular problems, such as blood clots, stroke and heart attack. As the disease progresses, the spleen can become enlarged as it has to to clear a greater number of blood cells than normal. In this study, as assessed by physical examination at baseline, patients did not have an enlarged spleen (spleen palpation) and a majority (approximately 70%) were considered less advanced, as they were previously treated with hydroxyurea only. The remaining patients were treated with multiple lines of therapy (approximately 30%).

“RESPONSE-2 is the first study of this scale to focus on patients with inadequately controlled polycythemia vera in a less advanced phase of the disease. The study supports the use of Jakavi as a second-line treatment option to help this patient population gain better control of their disease,” said lead study investigator, Francesco Passamonti, MD, the University of Insubria, Varese, Italy.

Pharma Oncology | Top News – Spring 2016

GSK Returns to War against Cancer

gsk1

April 3, 2016

It looked like the UK pharmaceuticals group GlaxoSmithKline (GSK) was declaring surrender in the war on cancer when the company agreed to sell its oncology drugs for $16 billion to Novartis in 2014. However, after two years, GSK returns to this war on cancer again.

 

FDA Grants Breakthrough Therapy Designation to Merck for KEYTRUDA® (pembrolizumab) in Classical Hodgkin Lymphoma (cHL)

merckApril 18, 2016

Merck, known as MSD outside the United States and Canada, has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to KEYTRUDA® (pembrolizumab). This is the company’s anti-PD-1 therapy which is used for the treatment of patients with refractory or relapsed classical Hodgkin lymphoma (cHL). This is the fourth Breakthrough Therapy Designation granted for KEYTRUDA.

 

Study Reveals that Opdivo from Bristol-Myers extends survival in head and neck cancer

Bristol-Myers

Apr 19, 2016

According to data from a late-stage study, the cancer immunotherapy drug of Bristol-Myers Squibb, Opdivo, assisted advanced head and neck cancer patients with a dismal prognosis live longer than other standard treatments.

 

AbbVie and argenx sign $685M deal for preclinical immuno-oncology

Abb-arg

April 21, 2016

AbbVie, a global biopharmaceutical company, and argenx, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for treating severe autoimmune diseases and cancer will work together to develop and commercialize ARGX-115. This is argenx’ preclinical-stage human antibody program that targets the novel immuno-oncology protein called GARP, which is believed to contribute to immuno-suppressive effects of T-cells.

 

AbbVie Agrees to Buy Stemcentrx

abbvie

April 28, 2016

Pharmaceutical company AbbVie Inc. has agreed to acquire Stemcentrx Inc., a cancer-drug developer, for $5.8 billion. This is part of AbbVie’s continuing aggressive push for building an oncology business.

 

European Medicines Agency Issues Positive Opinion for the Use of IMBRUVICA® for Chronic Lymphocytic Leukaemia Patients

abbvie

Apr 29, 2016

AbbVie, a global biopharmaceutical company, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion in favor of the use of IMBRUVICA® (ibrutinib) for treating adult patients with chronic lymphocytic leukemia (CLL). This follows the approval of U.S. Food and Drug Administration (FDA) IMBRUVICA for the first-line treatment of patients with CLL on March 4, 2016. This would be the fifth treatment indication for IMBRUVICA in the EU to date if approved by the European Commission (EC).

 

CHMP Recommends EU Approval for Roche’s Avastin in Combination with Tarceva for Treating Advanced Lung Cancer

roche1

29 April, 2016

Roche has announced that the European Union’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the use of Avastin® (bevacizumab) in combination with Tarceva® (erlotinib) for treating adult patients with advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) activating mutations. The most common type of lung cancer is NSCLC, which is the major cause of cancer-related death in Europe and across the world. Nearly 10-15 percent of Europeans with NSCLC have tumors with EGFR-activating mutations, which represents an estimated 33,000 cases in Europe per year, or 90 every day.

Roche’s Gazyvaro is recommended by CHMP for EU approval for treating follicular lymphoma

roche1

April 29, 2016

Roche has announced that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Gazyvaro® (obinutuzumab) in combination with bendamustine chemotherapy followed by Gazyvaro maintenance for the treatment of people with follicular lymphoma. Approximately 19,000 people in Europe are diagnosed with follicular lymphoma each year, which is the most common type of indolent (slow-growing) non-Hodgkin lymphoma. This sort of lymphoma is considered incurable, and the situation of most people deteriorate rapidly.

Bristol-Myers Squibb and AbbVie Announce the Approval of Empliciti™ (elotuzumab)by European Commission for the Treatment of Multiple Myeloma

bristol-abbvie

May 11, 2016

Bristol-Myers Squibb Company and AbbVie has announced that the European Commission has approved Empliciti™ (elotuzumab) for treating multiple myeloma as combination therapy with dexamethasone and Revlimid® (lenalidomide) in patients who have received at least one prior therapy. Now, Empliciti is the first and only immunostimulatory antibody approved for multiple myeloma in the European Union (EU).

European Commission Approves the Immuno-Oncology Combination, Opdivo® (nivolumab) + Yervoy® (ipilimumab) Regimen of Bristol-Myers Squibb, for Treatment of Advanced Melanoma

Bristol-Myers

May 11, 2016

Bristol-Myers Squibb Company has announced that the European Commission (EC) has approved Opdivo in combination with Yervoy for treating advanced (unresectable or metastatic) melanoma in adults. This combination represents the first and only approved combination of two Immuno-Oncology agents in the European Union (EU). Due to this approval, it has become legitimate to market Opdivo + Yervoy Regimen in all 28 Member States of the EU.

Novartis Separates its Pharmaceuticals Division into two business units: Novartis Pharmaceuticals and Novartis Oncology

novartis

May 17, 2016

Novartis has announced that it has created two business units reporting to the CEO: Novartis Oncology and Novartis Pharmaceuticals. The Innovative Medicines Division at Novartis will be formed by these business units. The Executive Committee of Novartis (ECN) will be effective from July 1, 2016, and the leader of each business will join this committee. Bruno Strigini will become CEO of Novartis Oncology and Paul Hudson will be appointed as CEO of Novartis Pharmaceuticals. Both will report directly to CEO of Novartis, Joseph Jimenez. In the meantime, David Epstein, currently Division Head and CEO, Novartis Pharmaceuticals, has decided to leave Novartis.

 

New Data on Opdivo (nivolumab) from Bristol-Myers Squibb Indicate Benefit in Heavily Pre-Treated Classical Hodgkin Lymphoma Patients

Bristol-Myers

June 10, 2016

Bristol-Myers Squibb Company has announced results from CheckMate -205, a multi-cohort, single-arm, non-comparative, Phase 2 registrational trial evaluating Opdivo (nivolumab) in classical Hodgkin lymphoma (cHL) patients. The results included patients who had relapsed or progressed after post-transplantation brentuximab vedotin and autologous hematopoietic stem cell transplantation (auto-HSCT). The primary endpoint of objective response rate (ORR) per an independent radiologic review committee (IRRC) was 66.3% (95% CI: 54.8-76.4). Median time to response was 2.1 months, and estimated median duration of remission was 7.8 months (95% CI: 6.6-NE). In an exploratory analysis, it was observed that over two-thirds (72.1%) of patients who did not respond to most recent prior brentuximab vedotin treatment did respond to Opdivo.

BLINCYTO® (Blinatumomab) Improved Overall Survival in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia

amgen

June 10, 2016

Amgen has announced new data from an interim analysis of the Phase 3 TOWER study, in which BLINCYTO® (blinatumomab) confirmed nearly two-fold increase in median overall survival (OS) compared to standard of care (SOC). The randomized, open-label TOWER study estimated the effectiveness of BLINCYTO versus SOC chemotherapy in adult patients with Philadelphiachromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Results from the analysis showed that median OS was 7.7 months (95 percent CI: 5.6, 9.6) for BLINCYTO compared to 4 months (95 percent CI: 2.9, 5.3) for SOC (stratified log-rank test p=.012; hazard ratio=0.71).

New Results from Pivotal Phase 3 Studies Show that Kyprolis® (Carfilzomib) Allows Patients with Relapsed Multiple Myeloma to Live Longer

amgen

June 10, 2016

Amgen has announced results from a post-hoc analysis of the pivotal Phase 3 ASPIRE study which emphasized the advantages of continued treatment with Kyprolis® (carfilzomib) in combination with lenalidomide and dexamethasone (KRd) in patients with relapsed multiple myeloma. Furthermore, separate sub-analyses of the Phase 3 ENDEAVOR study confirmed depth and efficacy of response benefits of Kyprolis plus dexamethasone (Kd). These results were presented at the 21st Congress of the European Hematology Association (EHA).

New Results from Pivotal Phase 3 Studies Show that Kyprolis® (Carfilzomib) Allows Patients with Relapsed Multiple Myeloma to Live Longer

Amgen Igea Luca Dezzani

amgen

June 10, 2016

Amgen has announced results from a post-hoc analysis of the pivotal Phase 3 ASPIRE study which emphasized the advantages of continued treatment with Kyprolis® (carfilzomib) in combination with lenalidomide and dexamethasone (KRd) in patients with relapsed multiple myeloma. Furthermore, separate sub-analyses of the Phase 3 ENDEAVOR study confirmed depth and efficacy of response benefits of Kyprolis plus dexamethasone (Kd). These results were presented at the 21st Congress of the European Hematology Association (EHA).

ASPIRE analysis results showed that cumulative rates of complete response or better (>CR) continued to increase over time in the KRd arm, most quickly in the first 15 months of treatment. Moreover, the progression-free survival (PFS) hazard ratio (HR) at 18 months was 0.58 (95 percent CI: 0.46-0.72), whereas the overall study HR at 31 months was 0.69 (95 percent CI: 0.57-0.83), possibly related to patients in the KRd arm receiving Kyprolis for a maximum of 18 months (EHA abstract #P275). Researchers evaluated PFS HR at 18 months following discontinuation of Kyprolis treatment in the KRd arm per the trial protocol. The most common all grade treatment-related adverse events in the ASPIRE trial included neutropenia (34.2 percent), anemia (25.5 percent), thrombocytopenia (22.4 percent), and fatigue (22.4 percent).

BLINCYTO® (Blinatumomab) Improved Overall Survival in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia

Amgen Igea Luca Dezzani

amgen

June 10, 2016

Amgen has announced new data from an interim analysis of the Phase 3 TOWER study, in which BLINCYTO® (blinatumomab) confirmed nearly two-fold increase in median overall survival (OS) compared to standard of care (SOC). The randomized, open-label TOWER study estimated the effectiveness of BLINCYTO versus SOC chemotherapy in adult patients with Philadelphiachromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Results from the analysis showed that median OS was 7.7 months (95 percent CI: 5.6, 9.6) for BLINCYTO compared to 4 months (95 percent CI: 2.9, 5.3) for SOC (stratified log-rank test p=.012; hazard ratio=0.71).

Max S. Topp, M.D., professor and head of haematology, University Hospital of Wuerzburg, Germany, said: “Acute lymphoblastic leukaemia is the most aggressive type of B-cell malignancy. The data presented today not only reinforce the potential of immunotherapy delivered by T cell engaging bispecific antibody constructs but also validate the efficacy of BLINCYTO in these heavily pretreated patients.”

“This is the first study of an immunotherapy to demonstrate overall survival benefit in adult patients with Ph-negative B-cell precursor relapsed or refractory ALL, a very complex-to-treat disease with limited treatment options. BLINCYTO is currently approved for the treatment of Ph-negative B-cell precursor relapsed or refractory ALL under accelerated approval, and we look forward to working with regulatory authorities for a full approval for BLINCYTO in this patient population,” said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen.

Astellas and Seattle Genetics Present ASG-15ME and ASG-22ME Phase I Clinical Data in Metastatic Urothelial Cancer

Astellas-Seattle.png

Astellas Pharma Inc. and Seattle Genetics, Inc. have presented first clinical data for ASG-15ME and ASG-22ME at the American Society of Clinical Oncology (ASCO) 51st Annual Meeting that was held in June 3-7, 2016 in Chicago, IL. ASG-15ME and ASG-22ME are investigational antibody-drug conjugates (ADCs) consisting of monoclonal antibodies that are designed to supply microtubule-disrupting agents selectively to tumor cells. This process is intended to spare non-targeted cells and thus minimize many of the toxic effects of traditional chemotherapy, in addition to enhance antitumor activity. ASG-15ME and ASG-22ME target SLITRK6 and Nectin-4, respectively. These are proteins that are highly expressed in urothelial cancers, particularly bladder cancer.

Len Reyno, M.D, senior vice president and chief medical officer, Agensys, an affiliate of Astellas, said: “Bladder cancer is the fifth most common cancer in the U.S. and there have been few treatment advances over the past three decades. For metastatic disease, the five-year survival rate is only 15 percent, representing a significant unmet need to identify additional treatment options. We are pleased to present these first data for ASG-15ME and ASG-22ME in urothelial cancers, which have a particularly high unmet medical need.”

“The clinical data from the phase I presented at ASCO from the ASG-15ME and ASG-22ME programs in heavily pretreated metastatic bladder cancer patients show a manageable safety profile along with objective response rates that are higher than historical rates seen with taxanes. We will continue enrolling patients in the ongoing phase 1 clinical trials to determine the recommended dose for further development,” said Jonathan Drachman, M.D., chief medical officer and executive vice president, Research and Development at Seattle Genetics.

 

Final Results Announced by Pfizer from Inotuzumab Ozogamicin Pivotal Phase 3 Study in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Pfizer Igea Luca Dezzani

pfizer_rgb_pos_canvassed[1]

June 12, 2016

Pfizer Inc. has announced the publication of findings from the Phase 3 INO-VATE ALL study in The New England Journal of Medicine’s online issue. This study, also known as Study 1022, is a randomized, open-label, Phase 3 study evaluating the efficacy and safety of inotuzumab ozogamicin as compared with investigator-choice chemotherapy in 326 adult patients with refractory or relapsed CD22-positive acute lymphoblastic leukemia (ALL). Results of the study showed improvement over chemotherapy on a number of measures including progression-free survival (PFS) and complete hematologic remission.

“Relapsed or refractory ALL is an aggressive leukemia in urgent need of new treatment options as about half of adult patients will not respond to chemotherapy or will see their disease return. The efficacy results seen in patients treated with inotuzumab ozogamicin in this study are impressive, particularly median progression-free survival, high rates of hematological remission and absence of minimal residual disease. These results suggest inotuzumab ozogamicin, if approved, could be a valuable new addition to currently available treatment options for ALL patients, including as a bridge to stem cell transplantation, which is the best chance for a cure at this stage of the disease,” said Hagop M. Kantarjian, M. D., lead study investigator and professor, The University of Texas MD Anderson Cancer Center.

As said by Mace Rothenberg, MD, Chief Development Officer, Oncology, Pfizer Global Product Development: “Adult patients with relapsed or refractory ALL have a five-year survival rate of less than 10 percent, making these patients particularly difficult to treat. To see remission rates and two-year survival rates that are more than doubled compared to standard of care chemotherapy is very gratifying. We believe these data add to the growing body of evidence that supports inotuzumab ozogamicin as an important potential treatment option in adults with relapsed or refractory ALL.”

 

Top 10 Best Healthcare Systems in the World

Top 10 Health Care System in the World - Igea - Luca Dezzani

Top 10 Health Care System in the World - Igea - Luca Dezzani

With the continuous rise in health care costs around the world, each country has been looking into their current health care system’s efficiency and value for money to promote the welfare and well-being of a greater population and achieve better health outcomes. In fact, many people consider US and Canada’s health care systems as those that would top the list. However, considering several aspects of a good health care system such as quality, accessibility, efficiency, equity and scores on three indicators of healthy lives, the Commonwealth Fund came up with a report that includes an overall ranking of countries which exhibit relatively good performance on all dimensions.

  1. UK

With $3,405 health expenditures per capita in 2011, UK tops the overall ranking for countries with the best health care system. Generally, upfront payments in the UK are not required. Aside from this, fees for GP consultation, ambulance and most major surgeries are free. However, despite all these health benefits, UK underperforms and ranked 10th on achieving healthy lives.

  1. Switzerland

In Switzerland, obtaining health insurance, which costs CHF 700 (USD 725) per year for adult and CHF 350 (USD 360) per year for children, is required for those who will stay in the country beyond three months. On the other hand GP fee in Switzerland typically costs CHF 100 (USD 105).

  1. Sweden

Unlike UK, Sweden requires upfront payments from individuals seeking medical care. They have to pay for their medical expenses but there is a certain limit of up to how much a person pays within a 12-month period. For example, in a particular region in Sweden, a person should only pay a maximum of 900 Swedish Krona (USD110) for medical expenses and 2200 Swedish Krona (USD 270) for prescription drugs in a year and everything will be free after that.

  1. Australia

In Australia, upfront payments are also required, which includes GP fee ranging from $50 to $80. However, most prescription drugs are subsidized by the Pharmaceutical Benefits Scheme (PBS) while treatment in public hospitals is completely covered by Medicare.

  1. Germany

Generally, Germany does not require upfront payments and since 2013, patients are no longer required to pay the GP consultation fee. However, about 85% of the population in Germany obtains insurance from the country’s non-profit Krankenkassen or “sickness funds” and those who earn more than €4,350 (USD 5000) may opt to obtain insurance from private companies.

  1. Netherlands

Compared to Switzerland, Netherlands does not require health insurance for individuals below 18 years old and for temporary visitors who will stay in the country for a less than a year. Obtaining health insurance typically costs 7.75% of a person’s salary or 5.65 % of one’s income, if self-employed.

  1. New Zealand

In New Zealand, GP fee typically costs $50 from 8:00 am to 6:00 pm which increases on weekends and night but is waived for children. Furthermore, if the person is a member of Primary Health Organization (PHO), he only has to pay $25 – $30 for GP consultation and $3/item for prescription drugs.

  1. Norway

The health care system in Norway is based on the principles of universal access, decentralization and free choice of provider. A person seeking professional care from a GP typically pays NOK 140 (USD 17) during the day and NOK 235 (USD 28) during the night. On the other hand, if he opts to consult a specialist, he has to pay NOK 315 (USD 39). Aside from this, drugs for chronic conditions are given on a blue prescription and are typically charged less.

  1. France

France requires upfront payments which are then reimbursed in partial or in full. However, starting November 2017, all upfront payments will be waived. In addition, all transactions in France are done through a smart card called Carte Vitale. The card is swiped to pay for all health expenses and will be reimbursed to the payor’s bank account within five banking days.

  1. Canada

Canada’s current health care system offers insurance plans that can cover the different health needs of its citizens. Private insurance companies offer a wide range of benefits that provincial health insurance cannot provide. These include, but not limited to, dental services, optometrists and prescription drugs. With its existing health care system, Canada possesses one of the highest life expectancies and lowest infant mortality rates.

 

Sources:

New Data on Opdivo (nivolumab) from Bristol-Myers Squibb Indicate Benefit in Heavily Pre-Treated Classical Hodgkin Lymphoma Patients

BMS Igea Luca Dezzani

BMS-logo

June 10, 2016

Bristol-Myers Squibb Company has announced results from CheckMate -205, a multi-cohort, single-arm, non-comparative, Phase 2 registrational trial evaluating Opdivo (nivolumab) in classical Hodgkin lymphoma (cHL) patients. The results included patients who had relapsed or progressed after post-transplantation brentuximab vedotin and autologous hematopoietic stem cell transplantation (auto-HSCT). The primary endpoint of objective response rate (ORR) per an independent radiologic review committee (IRRC) was 66.3% (95% CI: 54.8-76.4). Median time to response was 2.1 months, and estimated median duration of remission was 7.8 months (95% CI: 6.6-NE). In an exploratory analysis, it was observed that over two-thirds (72.1%) of patients who did not respond to most recent prior brentuximab vedotin treatment did respond to Opdivo.

Andreas Engert, M.D., lead investigator and professor of Internal Medicine, Hematology and Oncology, University Hospital of Cologne, Cologne, Germany, said: “There is currently no standard treatment option for classical Hodgkin lymphoma patients who have relapsed or whose disease has progressed after auto-HSCT and post-transplantation brentuximab vedotin. We are encouraged by the objective response rates and that the majority of responses were ongoing at the time of analysis in the CheckMate -205 trial evaluating Opdivo in these heavily pre-treated patients.”

“Classical Hodgkin lymphoma is a disease that disproportionately impacts young people, and there is a significant unmet need for patients who are not cured by the current standard-of-care treatments and who have a poor prognosis and very limited options. The data presented at EHA demonstrate that Opdivo is an important treatment option for patients whose disease has progressed after auto-HSCT and post-transplantation brentuximab vedotin,” said Jean Viallet, M.D., Global Clinical Research Lead, Oncology, Bristol-Myers Squibb.